Search Results - "Samelis, G"

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study by Kalofonos, H.P., Aravantinos, G., Kosmidis, P., Papakostas, P., Economopoulos, T., Dimopoulos, M., Skarlos, D., Bamias, A., Pectasides, D., Chalkidou, S., Karina, M., Koutras, A., Samantas, E., Bacoyiannis, C., Samelis, G.F., Basdanis, G., Kalfarentzos, F., Fountzilas, G.

“…Background:: Irinotecan (IRI) and oxaliplatin (OXA) are effective in the treatment of colorectal cancer. Previously untreated patients with advanced colorectal…”
Get full text

Gastroesophageal junction and gastroesophageal junction carcinoma : a short update by Ekmektzoglou, K A, Apostolopoulos, P, Samelis, G, Alexandrakis, G

“…Cancer of the gastroesophageal junction (GEJ), although rare, is now considered a separate entity with a distinct pathophysiological and molecular profile…”
Get more information

Genomic instability in ulcerative colitis: a prerequisite for cancer in the inflammatory colon? by Ekmektzoglou, K A, Samelis, G, Karagiannis, S, Zografos, G, Xanthos, T

“…Ulcerative colitis (UC), a chronic and relapsing idiopathic inflammatory disease of the colon, although not associated with an increased mortality compared to…”
Get more information

Gastrointestinal stromal tumours: Clinical overview, surgery and recent advances in imatinib mesylate therapy by Samelis, G.F, Ekmektzoglou, K.A, Zografos, G.C

“…Abstract Aims To review the clinical features of gastrointestinal stromal tumours (GISTs), the role of surgery and its principles and molecular targeted…”
Get full text

First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study by Papakostas, P, Kouroussis, Ch, Androulakis, N, Samelis, G, Aravantinos, G, Kalbakis, K, Sarra, E, Souglakos, J, Kakolyris, S, Georgoulias, V

“…The purpose was to evaluate the efficacy and safety profile of docetaxel as first-line chemotherapy for patients with locally advanced or metastatic biliary…”
Get full text

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group by Samelis, G.F, Skarlos, D, Bafaloukos, D, Kosmidis, P, Anagnostopoulos, A, Aravantinos, G, Dimopoulos, M.A

“…To consider the safety profile and therapeutic value of the combination of estramustine and mitoxantrone in a bimonthly schedule to treat hormone-refractory…”
Get full text

More than 54 months survival of a patient with lung adenocarcinoma after maintenance therapy with pemetrexed by Samelis, G, Ekmektzoglou, K, Giannakaki, S, Tsiakou, A

Get more information

Survival benefit during zoledronic acid and docetaxel-based chemotherapy in metastatic hormone-refractory prostate cancer patients: an institutional report by Samelis, G F, Ekmektzoglou, K A, Tsiakou, A, Giannakaki, S, Georgoulias, D, Christophilopoulos, K

“…To assess the overall survival (OS) of metastatic hormone-refractory prostate cancer (mHRPC) patients when treated with zoledronic acid (ZOL) in combination…”
Get more information

Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group by Xiros, N., Papacostas, P., Economopoulos, T., Samelis, G., Efstathiou, E., Kastritis, E., Kalofonos, H., Onyenadum, A., Skarlos, D., Bamias, A., Gogas, H., Bafaloukos, D., Samantas, E., Kosmidis, P.

“…Background:: In the present phase II multicenter study, we assessed the efficacy and tolerability of the combination of gemcitabine and carboplatin in patients…”
Get full text

Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study by Janinis, J., Papakostas, P., Samelis, G., Skarlos, D., Papagianopoulos, P., Fountzilas, G.

“…Backround: Oxaliplatin is a novel platinum derivative, which, combined with 5-fluorouracil (5-FU), and folinic acid (FA), demonstrates synergistic activity in…”
Get full text

Metastatic melanoma: case report of a patient with seventeen months of complete remission, five years survival and review of the literature by Samelis, G F, Ekmektzoglou, K A, Tsiakou, A, Konstadoulakis, M M

“…Melanoma, an aggressive, therapy-resistant malignancy of melanocytes, is the most serious type of skin cancer affecting young and middle-aged people. Therapy…”
Get more information

6589 Biweekly treatment with Docetaxel-Gemcitabine and Erlotinib in patients with metastatic and/or unresectable pancreatic cancer offers a survival benefit by Samelis, G, Tsiakou, A, Karamanides, M, Pelechrini, M, Zaganides, A, Ekmektzoglou, K

Get full text

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy : a multicenter phase II trial by ALEXOPOULOS, K, KOUROUSSIS, C, GEORGOULIAS, V, ANDROULAKIS, N, PAPADAKIS, E, VASLAMATZIS, M, KAKOLYRIS, S, SAMELIS, G, PATILA, E, VOSSOS, A, SAMANTAS, E

“…To investigate the activity of docetaxel and granulocyte colony-stimulating factor support (G-CSF) in patients with advanced non-small-cell lung cancer (NSCLC)…”
Get full text

Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187) by Samelis, G F, Stathopoulos, G P, Kotsarelis, D, Dontas, I, Frangia, C, Karayannacos, P E

“…This study is related to the serious side effects of Doxorubicin-cardiotoxicity and serum lipid caused by the drug's cumulative effect. Studies were performed…”
Get more information

P-214 Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study by Tsoukalas, N., Christopoulou, A., Anastopoulou, G., Papandreou, C., Timotheadou, E., Athanasiadis, I., Koumarianou, A., Peroukidis, S., Samelis, G., Psyrri, A., Kapodistrias, N., Nikolakopoulos, A., Andreadis, C., Ardavanis, A., Samantas, E., Bokas, A., Barbounis, V., Kentepozidis, N., Mavroudis, D., Athanasiadis, A., Papakotoulas, P., Boukovinas, I.

Get full text

PO-45: Cancer-associated thrombosis (CAT) in gynecological cancers: data from ACT4CAT study by Tsoukalas, N., Christopoulou, A., Timotheadou, E., Athanasiadis, I., Koumarianou, A., Peroukidis, S., Samelis, G., Psyrri, A., Kapodistrias, N., Nikolakopoulos, A., Andreadis, C., Ardavanis, A., Samantas, E., Papandreou, C., Mavroudis, D., Bokas, A., Barbounis, V., Kentepozidis, N., Athanasiadis, A., Papakotoulas, P., Boukovinas, I.

Get full text

Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials by Bacoyiannis, C, Dimopoulos, M A, Kalofonos, H P, Nicolaides, C, Aravantinos, G, Bafaloukos, D, Samelis, G, Onyenadum, A, Kiamouris, Ch, Skarlos, D, Pavlidis, N, Triantafillidis, A, Kosmidis, P

“…The aim of this study is firstly to determine the response rates and toxicity of two regimens containing vinblastine (VBL) in combination with interferon-gamma…”
Get more information

TEMPORARY REMOVAL: PO-45: Cancer-associated thrombosis (CAT) in gynecological cancers: data from ACT4CAT study by Tsoukalas, N, Christopoulou, A, Timotheadou, E, Athanasiadis, I, Koumarianou, A, Peroukidis, S, Samelis, G, Psyrri, A, Kapodistrias, N, Nikolakopoulos, A, Andreadis, C, Ardavanis, A, Samantas, E, Papandreou, C, Mavroudis, D, Bokas, A, Barbounis, V, Kentepozidis, N, Athanasiadis, A, Papakotoulas, P, Boukovinas, I

“…The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the…”
Get full text

Should patients with active urological cancers receive thromboprophylaxis for Cancer Associated Thrombosis (CAT)? by Tsoukalas, N.G., Christopoulou, A., Timotheadou, E., Koumarianou, A., Athanasiadis, I., Peroukidis, S., Samelis, G., Psyrri, A., Papandreou, C., Kapodistrias, N., Papatsimpas, G., Papakostas, P., Aravantinos, G., Ziras, N., Nikolakopoulos, A., Demiri, S., Andreadis, C., Ardavanis, A., Sgouros, I., Bokas, A., Barbounis, V., Kentepozidis, N., Mavroudis, D., Papakotoulas, P., Boukovinas, I.

Get full text

Survival benefit with erlotinib-based chemotherapy in unoperable recurrent and/or metastatic pancreatic cancer by Samelis, G. F., Tsiakou, A., Zaganides, A., Ekmektzoglou, K.

“…Abstract only…”
Get full text